世界の未分化リンパ腫キナーゼ阻害剤市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Anaplastic Lymphoma Kinase Inhibitors Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-105X00925 • 出版社/出版日：GlobalInfoResearch / 2021年5月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、未分化リンパ腫キナーゼ阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。未分化リンパ腫キナーゼ阻害剤の種類別市場規模（クリゾチニブ、セリチニブ、アレクチニブ塩酸塩）、用途別市場規模（NSCLC、乳がん、大腸がん、神経芽細胞腫、卵巣がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・未分化リンパ腫キナーゼ阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Betta Pharmaceutcials Co., Ltd.、Crtierium, Inc.、F.Hoffman-La Roche Ltd.、Helsinn Therapeutics、Novartis AG.、Oncoethix GmbH、Pfizer, Inc.、Takeda Pharmaceutical Co., Ltd.、Xcovery Holding Company, LLC、Tesaro, Inc. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：クリゾチニブ、セリチニブ、アレクチニブ塩酸塩 ・用途別分析2016年-2026年：NSCLC、乳がん、大腸がん、神経芽細胞腫、卵巣がん、その他 ・未分化リンパ腫キナーゼ阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・未分化リンパ腫キナーゼ阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・未分化リンパ腫キナーゼ阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・未分化リンパ腫キナーゼ阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・未分化リンパ腫キナーゼ阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Anaplastic Lymphoma Kinase Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anaplastic Lymphoma Kinase Inhibitors size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Anaplastic Lymphoma Kinase Inhibitors market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Anaplastic Lymphoma Kinase Inhibitors market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Crizotinib
Ceritinib
Alectinib Hydrochloride

Market segment by Application can be divided into
NSCLC
Breast Cancer
Colorectal Cancer
Neuroblastoma
Ovarian Cancer
Others

The key market players for global Anaplastic Lymphoma Kinase Inhibitors market are listed below:
Betta Pharmaceutcials Co., Ltd.
Crtierium, Inc.
F.Hoffman-La Roche Ltd.
Helsinn Therapeutics
Novartis AG.
Oncoethix GmbH
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
Xcovery Holding Company, LLC
Tesaro, Inc.

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Anaplastic Lymphoma Kinase Inhibitors Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Alectinib Hydrochloride
1.3 Market Analysis by Application
1.3.1 Overview: Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 NSCLC
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Neuroblastoma
1.3.6 Ovarian Cancer
1.3.7 Others
1.4 Global Anaplastic Lymphoma Kinase Inhibitors Market Size & Forecast
1.4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value (2016-2026))
1.4.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume (2016-2026)
1.4.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2016-2026) & (USD/MT)
1.5 Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity Analysis
1.5.1 Global Anaplastic Lymphoma Kinase Inhibitors Total Production Capacity (2016-2026)
1.5.2 Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Anaplastic Lymphoma Kinase Inhibitors Market Drivers
1.6.2 Anaplastic Lymphoma Kinase Inhibitors Market Restraints
1.6.3 Anaplastic Lymphoma Kinase Inhibitors Trends Analysis
2 Manufacturers Profiles
2.1 Betta Pharmaceutcials Co., Ltd.
2.1.1 Betta Pharmaceutcials Co., Ltd. Details
2.1.2 Betta Pharmaceutcials Co., Ltd. Major Business
2.1.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.1.4 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Crtierium, Inc.
2.2.1 Crtierium, Inc. Details
2.2.2 Crtierium, Inc. Major Business
2.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.2.4 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 F.Hoffman-La Roche Ltd.
2.3.1 F.Hoffman-La Roche Ltd. Details
2.3.2 F.Hoffman-La Roche Ltd. Major Business
2.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.3.4 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Helsinn Therapeutics
2.4.1 Helsinn Therapeutics Details
2.4.2 Helsinn Therapeutics Major Business
2.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.4.4 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Novartis AG.
2.5.1 Novartis AG. Details
2.5.2 Novartis AG. Major Business
2.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.5.4 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Oncoethix GmbH
2.6.1 Oncoethix GmbH Details
2.6.2 Oncoethix GmbH Major Business
2.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.6.4 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Pfizer, Inc.
2.7.1 Pfizer, Inc. Details
2.7.2 Pfizer, Inc. Major Business
2.7.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.7.4 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Takeda Pharmaceutical Co., Ltd.
2.8.1 Takeda Pharmaceutical Co., Ltd. Details
2.8.2 Takeda Pharmaceutical Co., Ltd. Major Business
2.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.8.4 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Xcovery Holding Company, LLC
2.9.1 Xcovery Holding Company, LLC Details
2.9.2 Xcovery Holding Company, LLC Major Business
2.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.9.4 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 Tesaro, Inc.
2.10.1 Tesaro, Inc. Details
2.10.2 Tesaro, Inc. Major Business
2.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product and Services
2.10.4 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Anaplastic Lymphoma Kinase Inhibitors Sales by Manufacturer
3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Anaplastic Lymphoma Kinase Inhibitors
3.4 Market Concentration Rate
3.4.1 Top 3 Anaplastic Lymphoma Kinase Inhibitors Manufacturer Market Share
3.4.2 Top 6 Anaplastic Lymphoma Kinase Inhibitors Manufacturer Market Share
3.5 Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Anaplastic Lymphoma Kinase Inhibitors Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Region
4.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2016-2026)
4.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2016-2026)
4.2 North America Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026)
4.3 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026)
4.4 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026)
4.5 South America Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026)
4.6 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Type (2016-2026)
5.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2016-2026)
5.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Application (2016-2026)
6.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2016-2026)
6.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2026)
7.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2026)
7.3 North America Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
7.3.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2016-2026)
7.3.2 North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2026)
8.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2026)
8.3 Europe Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
8.3.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2016-2026)
8.3.2 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2026)
9.2 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2026)
9.3 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Market Size by Region
9.3.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2026)
10.2 South America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2026)
10.3 South America Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
10.3.1 South America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2016-2026)
10.3.2 South America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2026)
11.2 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2026)
11.3 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
11.3.1 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Anaplastic Lymphoma Kinase Inhibitors Typical Distributors
12.3 Anaplastic Lymphoma Kinase Inhibitors Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type, (USD Million), 2021-2026
Table 2. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application, (USD Million), 2021-2026
Table 3. Betta Pharmaceutcials Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 4. Betta Pharmaceutcials Co., Ltd. Major Business
Table 5. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 6. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Crtierium, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. Crtierium, Inc. Major Business
Table 9. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 10. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. F.Hoffman-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 12. F.Hoffman-La Roche Ltd. Major Business
Table 13. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 14. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Helsinn Therapeutics Basic Information, Manufacturing Base and Competitors
Table 16. Helsinn Therapeutics Major Business
Table 17. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 18. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Novartis AG. Basic Information, Manufacturing Base and Competitors
Table 20. Novartis AG. Major Business
Table 21. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 22. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Oncoethix GmbH Basic Information, Manufacturing Base and Competitors
Table 24. Oncoethix GmbH Major Business
Table 25. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 26. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer, Inc. Major Business
Table 29. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 30. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Takeda Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 32. Takeda Pharmaceutical Co., Ltd. Major Business
Table 33. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 34. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Xcovery Holding Company, LLC Basic Information, Manufacturing Base and Competitors
Table 36. Xcovery Holding Company, LLC Major Business
Table 37. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 38. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Tesaro, Inc. Basic Information, Manufacturing Base and Competitors
Table 40. Tesaro, Inc. Major Business
Table 41. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product and Services
Table 42. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Manufacturer (2019-2021e) & (MT)
Table 44. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Anaplastic Lymphoma Kinase Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity by Company, (MT): 2020 VS 2021
Table 47. Head Office and Anaplastic Lymphoma Kinase Inhibitors Production Site of Key Manufacturer
Table 48. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2016-2021e) & (MT)
Table 49. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2021-2026) & (MT)
Table 50. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2016-2021e) & (USD Million)
Table 51. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 52. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2021e) & (MT)
Table 53. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2021-2026) & (MT)
Table 54. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2016-2021e) & (USD Million)
Table 55. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 56. Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2016-2021e) & (USD/MT)
Table 57. Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2021-2026) & (USD/MT)
Table 58. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2021e) & (MT)
Table 59. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2021-2026) & (MT)
Table 60. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2016-2021e) & (USD Million)
Table 61. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 62. Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2016-2021e) & (USD/MT)
Table 63. Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2021-2026) & (USD/MT)
Table 64. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2016-2021e) & (MT)
Table 65. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2021-2026) & (MT)
Table 66. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 67. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 68. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2021e) & (MT)
Table 69. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2021-2026) & (MT)
Table 70. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2021e) & (MT)
Table 71. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2021-2026) & (MT)
Table 72. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2016-2021e) & (MT)
Table 73. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2021-2026) & (MT)
Table 74. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 75. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 76. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2021e) & (MT)
Table 77. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2021-2026) & (MT)
Table 78. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2021e) & (MT)
Table 79. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2021-2026) & (MT)
Table 80. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2016-2021e) & (MT)
Table 81. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2021-2026) & (MT)
Table 82. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2016-2021e) & (USD Million)
Table 83. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 84. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2021e) & (MT)
Table 85. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2021-2026) & (MT)
Table 86. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2021e) & (MT)
Table 87. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2021-2026) & (MT)
Table 88. South America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2016-2021e) & (MT)
Table 89. South America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2021-2026) & (MT)
Table 90. South America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 91. South America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 92. South America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2021e) & (MT)
Table 93. South America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2021-2026) & (MT)
Table 94. South America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2021e) & (MT)
Table 95. South America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2021-2026) & (MT)
Table 96. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2016-2021e) & (MT)
Table 97. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2021-2026) & (MT)
Table 98. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 99. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 100. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2016-2021e) & (MT)
Table 101. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2021-2026) & (MT)
Table 102. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2016-2021e) & (MT)
Table 103. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2021-2026) & (MT)
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Anaplastic Lymphoma Kinase Inhibitors Typical Distributors
Table 107. Anaplastic Lymphoma Kinase Inhibitors Typical Customers
List of Figures
Figure 1. Anaplastic Lymphoma Kinase Inhibitors Picture
Figure 2. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2020
Figure 3. Crizotinib
Figure 4. Ceritinib
Figure 5. Alectinib Hydrochloride
Figure 6. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2020
Figure 7. NSCLC
Figure 8. Breast Cancer
Figure 9. Colorectal Cancer
Figure 10. Neuroblastoma
Figure 11. Ovarian Cancer
Figure 12. Others
Figure 13. Global Anaplastic Lymphoma Kinase Inhibitors Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 14. Global Anaplastic Lymphoma Kinase Inhibitors Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. United States Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. Canada Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Mexico Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Germany Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. France Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. United Kingdom Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Russia Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Italy Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. China Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Japan Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Korea Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. India Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Australia Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Brazil Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Egypt Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Saudi Arabia Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. South Africa Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Turkey Anaplastic Lymphoma Kinase Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. Global Anaplastic Lymphoma Kinase Inhibitors Sales (2016-2026) & (MT)
Figure 35. Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity (2016-2026) & (MT)
Figure 36. Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity by Geographic Region: 2020 VS 2021
Figure 37. Anaplastic Lymphoma Kinase Inhibitors Market Drivers
Figure 38. Anaplastic Lymphoma Kinase Inhibitors Market Restraints
Figure 39. Anaplastic Lymphoma Kinase Inhibitors Market Trends
Figure 40. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Manufacturer in 2020
Figure 41. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Manufacturer in 2020
Figure 42. Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 43. Top 3 Anaplastic Lymphoma Kinase Inhibitors Manufacturer (Revenue) Market Share in 2020
Figure 44. Top 6 Anaplastic Lymphoma Kinase Inhibitors Manufacturer (Revenue) Market Share in 2020
Figure 45. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2016-2026)
Figure 46. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2016-2026)
Figure 47. North America Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026) & (USD Million)
Figure 48. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026) & (USD Million)
Figure 49. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026) & (USD Million)
Figure 50. South America Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026) & (USD Million)
Figure 51. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue (2016-2026) & (USD Million)
Figure 52. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2016-2026)
Figure 53. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2016-2026)
Figure 54. Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2016-2026) & (USD/MT)
Figure 55. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2016-2026)
Figure 56. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2016-2026)
Figure 57. Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2016-2026) & (USD/MT)
Figure 58. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2016-2026)
Figure 59. North America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2016-2026)
Figure 60. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2016-2026)
Figure 61. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2016-2026)
Figure 62. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2016-2026)
Figure 63. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2016-2026)
Figure 64. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2016-2026)
Figure 65. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2016-2026)
Figure 66. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2016-2026)
Figure 67. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2016-2026)
Figure 68. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2016-2026)
Figure 69. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2016-2026)
Figure 70. South America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2016-2026)
Figure 71. South America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2016-2026)
Figure 72. South America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2016-2026)
Figure 73. South America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2016-2026)
Figure 76. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2016-2026)
Figure 77. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2016-2026)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

---